Low-Grade Serous Ovarian Cancer: One MEK Inhibitor Worked, Its Cousin Didn't
Two MEK inhibitors were tested in the same chemo-resistant disease, against the same kind of comparator, within a few years of each other — and one worked while the other didn't. The disagreement isn't about the MEK pathway. It's about whether a drug class result is a class result at all.
Priya M. trains for one half-marathon a year, a habit she picked up during her first round of chemotherapy four years ago as a way to reclaim some part of her schedule from appointments, and she has kept it up through two subsequent relapses of a disease her oncologist has described more than once as unusually stubborn. She was 37 when a large pelvic mass turned out to be low-grade serous ovarian carcinoma, a histology that behaves nothing like the high-grade serous disease most ovarian cancer trials are built around: it grows slowly, but it responds poorly to the platinum-based chemotherapy that is standard everywhere else in ovarian cancer, and her own course has borne that out — stable disease at best across two prior chemotherapy regimens, never a real response.
Molecular testing on her original tumor found a KRAS mutation, placing her disease squarely in the MAPK-pathway-altered subset that low-grade serous carcinoma is now understood to frequently carry, which is the actual mechanistic argument for targeting the pathway directly rather than cycling through another chemotherapy regimen unlikely to work any better than the last two. But the evidence behind that argument is not uniform across the drug class it names. GOG-0281, the trial that established trametinib's benefit in recurrent low-grade serous ovarian cancer, found a real and clinically meaningful PFS improvement over physician's-choice chemotherapy — roughly 13 months against 7.2. MILO/ENGOT-ov11, a comparably designed trial testing binimetinib against the same kind of chemotherapy comparator in the same disease, found no PFS benefit at all. Same drug class, same target, same disease, and two trials that disagree — which means the honest reading of Priya's own eligibility is not "she has a MAPK-altered LGSOC, so a MEK inhibitor is indicated," but specifically whether trametinib, the one MEK inhibitor with a positive trial behind it in this exact disease, is accessible and appropriate for her, independent of whatever her insurance formulary happens to prefer. Her plan's own formulary, as it happens, lists binimetinib preferentially — turning what should be a straightforward reading of two trials into a prior-authorization argument the team will need to win on the strength of that divergence, not on drug-class language alone.
Same class, same disease, two different trials
I'd pursue trametinib specifically, not a MEK inhibitor generically. GOG-0281 showed a real PFS benefit in exactly her disease — about 13 months against 7.2 for physician's-choice chemotherapy. MILO/ENGOT-ov11 tested binimetinib in the same disease against a similar comparator and found nothing. Whatever her formulary prefers, substituting one for the other on the assumption that mechanism predicts response is exactly the assumption those two trials together disprove.
I'm not arguing for binimetinib — I agree the two trials diverge and that matters. But I want the size of trametinib's benefit read carefully: physician's-choice chemotherapy performs poorly across the board in chemo-resistant low-grade serous disease, which means part of that 13-versus-7.2 gap may be the comparator arm's known weakness in this histology, not solely trametinib's strength.
That's a real caution about magnitude, but it doesn't touch the actual disagreement — whether trametinib specifically, rather than the MEK inhibitor class generally, is the right call. A weaker comparator doesn't make a negative trial for a different drug turn positive.
One thing worth being precise about: neither trial required a MAPK-pathway mutation to enroll. Her KRAS finding is a good biological reason to expect trametinib to work well for her, but it isn't a separate eligibility hurdle she has to clear on top of the trial data — the trial itself is what actually established the indication, and she fits its population regardless of what her mutation status adds on top.
Agreed: trametinib initiated, with baseline and follow-up ophthalmologic and cardiac (echocardiogram) monitoring built into the regimen given the drug's specific known toxicity profile.
Fully agreed, unlike most debates in this series: all three voices converged on trametinib specifically, with the pharmacologist's magnitude caution folded into how the response is later interpreted rather than into which drug is started today.